查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年自閉症譜系治療市場預測 - 按藥物治療、疾病、年齡層、配銷通路和地區進行的全球分析
市場調查報告書
商品編碼
1339996

到 2030 年自閉症譜系治療市場預測 - 按藥物治療、疾病、年齡層、配銷通路和地區進行的全球分析

Autism Spectrum Disorder Treatment Market Forecasts to 2030 - Global Analysis By Drug Therapy, Disease (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder and Other Diseases), Age Group, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球自閉症譜系治療市場規模為 21 億美元，預計到 2030 年將達到 43 億美元，預測期內年複合成長率為 9.9%。

自閉症譜系障礙（ASD）是一種由大腦變化引起的發育障礙。一些自閉症譜系障礙 (ASD) 患者被認為患有遺傳性疾病。其他原因尚不清楚。據科學家稱，一個人最典型的發展方式被認為會因多種導致自閉症譜系障礙（ASD）的原因而發生變化。阿斯伯格症候群、自閉症和廣泛性發育障礙（PDD）都屬於自閉症譜系（ASD）範疇。

據美國醫學會（AMA）預測，2020年美國醫療保健支出將成長9.7%，達到4.1兆美元，即人均12,530美元。

市場動態：

促進因素

  • 全球自閉症譜系障礙人數增加。
  • 自閉症譜系障礙 (ASD) 診斷患病率的上升增加了對有效干涉、治療和支持系統的需求。這刺激了從行為療法到藥物干涉等多種治療方法的研究、創新和投資。隨著社會對自閉症譜系障礙(ASD) 的認知越來越深刻，並尋求改善自閉症譜系障礙(ASD) 患者的生活品質，多樣化和綜合治療選擇的市場正在擴大、發展和專業化，以滿足自閉症譜系障礙(ASD) 患者不斷變化的需求。客製化方法。

抑制因素

  • 治療和診斷費用高。
  • 治療、干涉、藥物和診斷的費用讓許多家庭和醫療保健系統望而卻步。這種經濟負擔往往限制了獲得綜合護理的機會，導致治療可用性和品質的不平等。因此，必須解決財務障礙，以確保自閉症譜系障礙患者得到及時有效的干涉。努力降低成本、擴大保險覆蓋範圍和推廣無障礙支持系統對於克服這一障礙並為自閉症譜系障礙患者取得更好的結果至關重要。

機會

  • 提高對 ASD 的認知和投資。
  • 公眾對自閉症譜系障礙 (ASD) 的了解不斷增加，對可及且有效的干涉措施的需求也隨之增加，從而推動了治療方法的研究和創新。這種認知也推動了治療、藥物和輔助技術的進步，並吸引了公共和私營部門增加投資。擴大的資金池將有助於開發客製化的、基於證據的解決方案，以滿足自閉症譜系障礙患者的獨特需求。這種認可和投資的協同效應為改善自閉症譜系障礙患者的治療結果和生活品質鋪平了道路。

威脅

  • 有關產品核可的嚴格法規。
  • 治療、藥物和干涉措施的複雜而冗長的核准流程減緩了創新治療的可用性，並阻礙了自閉症譜系障礙患者及時獲得治療。儘管對於患者安全而言是必要的，但由於相關的時間和成本限制，這些法規可能會阻礙該領域的投資和研究。平衡嚴格的標準與自閉症譜系障礙患者不斷變化的需求的緊迫性是必要的，以確保有前景的治療方法有效地通過法規環境，最大限度地減少延誤並最佳化患者的治療結果。這是至關重要的。

COVID-19 的影響：

  • COVID-19 的爆發對自閉症譜系障礙 (ASD) 治療市場產生了重大影響。醫療保健服務、治療課程和學校停課的中斷崩壞了自閉症譜系障礙患者通常的支持系統。雖然遠端醫療和遠程干涉受到關注，但面對面治療面臨挑戰。供應鏈中斷影響了藥品的供應。這場大流行凸顯了對有彈性和適應性的治療方法的需求。隨著社會的復甦，以及遠端醫療解決方案的進步，人們將重新關注可及且彈性的干涉措施以及混合干涉措施，以確保為自閉症患者提供持續和有效的支持。這種重點放在可能塑造未來的方法上ASD 治療。
  • 預計抗精神病藥物市場在預測期內將是最大的市場
  • 抗精神病藥物在自閉症譜系治療市場中佔據很大佔有率。儘管抗精神病藥物並未被專門批准用於治療自閉症譜系障礙，但有時會在仿單標示外開具抗精神病藥物來控制攻擊性、易怒和重複行為等行為症狀。然而，由於潛在的副作用和長期有效性的證據有限，人們對其使用存在擔憂。正在進行的研究旨在更好地了解自閉症譜系障礙(ASD) 的有效性和安全性，在解決具有挑戰性的行為和最大限度地減少與這些藥物相關的風險之間取得平衡。我們的目標是為自閉症譜系障礙(ASD) 患者提供更全面、資訊的治療。
  • 醫院藥房業務預計在預測期內年複合成長率最高
  • 在預測期內，醫院藥房在自閉症譜系治療市場中的年複合成長率最高。提供基本藥物、治療和干涉措施。這些藥房提供處方藥，如抗精神病藥、抗抑鬱藥和其他可滿足自閉症譜系障礙患者不同需求的治療藥物。我們還確保適當的藥物管理、劑量和給藥，並為護理人員和醫療保健專業人員提供指導和支持。醫院藥房通過最佳化治療計劃、促進醫療團隊之間的協作以及確保 ASD 患者在受控和監督的環境中接受所需的治療，幫助改善治療結果和品質。

佔比最大的地區

北美佔據重要地位，預計在預測期內將佔據最大佔有率。該地區擁有先進的醫療基礎設施、研究能力和不斷提高的意識，以及成熟的製藥行業和研究機構，促進了自閉症譜系障礙治療的創新。強大的保險覆蓋範圍和獲得醫療保健的機會有助於改善自閉症譜系障礙患者獲得治療的機會。此外，北美醫療專業人員、研究人員和倡導團體之間的合作方法支持制定循證干涉措施和量身定做的治療計劃。這些要素使北美成為塑造 ASD 治療格局的關鍵參與者，重點是改善治療結果和患者福祉。

複合年複合成長率最高的地區

亞太地區要素其龐大且多樣化的人口、不斷提高的意識以及不斷發展的醫療基礎設施，在自閉症譜系治療市場中擁有最高的年複合成長率。我成長了。該地區自閉症譜系障礙患者患病率的上升增加了對有效干涉措施的需求，並為研究、創新和治療方法的投資創造了機會。遠端醫療和數位平台的使用範圍正在擴大，有助於提供遠程支持和治療。

免費客製化服務：

訂閱此報告的客戶將收到以下免費客製化選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（注：基於可行性檢查）
  • 競爭標杆管理
    • 根據產品系列、地域分佈和戰略聯盟對主要企業進行基準測試

目錄

第1章 執行摘要

第2章 前言

  • 執行摘要
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 資料挖掘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球自閉症譜系治療市場：通過藥物治療

  • 抗精神病藥
  • 抗抑鬱藥
  • 興奮劑
  • 安眠藥
  • 其他藥物

第6章 全球自閉症譜系治療市場：按疾病分類

  • 自閉症
  • 阿斯伯格症候群
  • 廣泛性發育障礙 (PDD)
  • 其他疾病

第7章 全球自閉症譜系治療市場：按年齡層

  • 孩子
  • 成人

第8章 全球自閉症譜系治療市場：按配銷通路分類

  • 醫院藥房
  • 藥店/零售藥房
  • 網上藥房

第9章 全球自閉症譜系治療市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 契約、夥伴關係、聯盟和合資企業
  • 收購和合併
  • 新產品上市
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Curemark, LLC
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Alembic Pharmaceuticals Limited
  • Aurobindo Pharma Ltd.
  • Merck & Co., Inc.
  • Axial Therapeutics Inc.
  • Novartis AG.
  • F. Hoffmann-La Roche Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • PaxMedica
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Q BioMed Inc.
  • Stalicla
  • Teva Pharmaceutical Industries Ltd.
  • Yamo Pharmaceuticals
  • Zynerba Pharmaceuticals, Inc
Product Code: SMRC23703

According to Stratistics MRC, the Global Autism Spectrum Disorder Treatment Market is accounted for $2.1 billion in 2023 and is expected to reach $4.3 billion by 2030 growing at a CAGR of 9.9% during the forecast period. A developmental condition brought on by variations in the brain is known as autism spectrum disorder (ASD). Some individuals with autism spectrum disorder (ASD) have a recognized distinction, like a genetic illness. Additional causes are still unknown. The most typical ways that people develop are thought to be altered by a number of reasons that contribute to autism spectrum disorder (ASD), according to scientists. Asperger's syndrome, autistic disorder, and pervasive developmental disorder (PDD) are all included in the category of autism spectrum disorder (ASD).

According to American Medical Association (AMA), health spending in the U.S. increased by 9.7% in 2020 to $4.1 trillion or $12,530 per capita.

Market Dynamics:

Driver:

  • Global rise in Autism Spectrum Disorder.
  • The rising prevalence of ASD diagnoses has created a growing demand for effective interventions, therapies, and support systems. This has fueled research, innovation, and investment in developing a wide range of treatments, from behavioral therapies to pharmaceutical interventions. As societies become more aware of ASD and seek improved quality of life for affected individuals, the market for diverse and comprehensive treatment options expands, offering opportunities for advancement, specialization, and tailored approaches to cater to the evolving needs of those with ASD.

Restraint:

  • High cost for treatment and diagnosis.
  • The expenses associated with therapies, interventions, medications, and diagnostic procedures can be prohibitive for many families and healthcare systems. This financial burden often limits access to comprehensive care, resulting in inequities in treatment availability and quality. As a consequence, addressing the affordability barrier becomes crucial to ensuring that individuals with ASD receive timely and effective interventions. Efforts to reduce costs, increase insurance coverage, and promote accessible support systems are essential to overcoming this obstacle and ensuring better outcomes for those with ASD.

Opportunity:

  • Rising awareness pertaining ASD and growing number of investments.
  • Greater public understanding of ASD has led to heightened demand for accessible and effective interventions, encouraging research and innovation in treatment methods. This awareness has also attracted increased investment from both the public and private sectors, driving advancements in therapies, medications, and assistive technologies. The expanding pool of funds allows for the development of tailored and evidence-based solutions that address the unique needs of individuals with ASD. This synergy of awareness and investment paves the way for improved treatment outcomes and enhanced quality of life for those affected by ASD.

Threat:

  • Stringent regulations pertaining to product approval.
  • The complex and lengthy approval processes for therapies, medications, and interventions can delay the availability of innovative treatments, hindering timely access for individuals with ASD. These regulations, while necessary for patient safety, can deter investment and research in the field due to the associated time and cost constraints. Balancing rigorous standards with the urgency to address the evolving needs of those with ASD is essential to ensuring that promising treatments can navigate the regulatory landscape efficiently and effectively, minimizing delays and optimizing patient outcomes.

COVID-19 Impact:

  • The COVID-19 pandemic has significantly impacted the Autism Spectrum Disorder (ASD) treatment market. Disruptions in healthcare services, therapy sessions, and school closures have disrupted the usual support systems for individuals with ASD. Telehealth and remote interventions gained prominence, but in-person therapies faced challenges. Supply chain disruptions affected medication availability. The pandemic highlighted the need for resilient and adaptable treatment approaches. As societies recover, a renewed focus on accessible and flexible interventions, along with advancements in telehealth solutions, may shape the future of ASD treatment, emphasizing a blended approach to ensure continuous and effective support for individuals with autism.
  • The antipsychotic drugs segment is expected to be the largest during the forecast period
  • The antipsychotic drugs have a significant share in the Autism Spectrum Disorder Treatment market. While not specifically approved for ASD, they are sometimes prescribed off-label to manage behavioral symptoms such as aggression, irritability, and repetitive behaviors. However, their use raises concern due to potential side effects and limited evidence of long-term benefits. Ongoing research aims to better understand their efficacy and safety in the context of ASD, seeking to strike a balance between addressing challenging behaviors and minimizing the risks associated with these medications, thereby contributing to a more comprehensive and informed treatment landscape for individuals with ASD.
  • The hospital pharmacies segment is expected to have the highest CAGR during the forecast period
  • The hospital pharmacies have the highest CAGR within the Autism Spectrum Disorder Treatment market over the forecast period. Providing access to essential medications, therapies, and interventions. These pharmacies dispense prescribed medications such as antipsychotics, antidepressants, and other therapies that address the diverse needs of individuals with ASD. They ensure proper medication management, dosage, and administration, while also offering guidance and support to caregivers and healthcare professionals. Hospital pharmacies contribute to optimizing treatment plans, facilitating collaboration between medical teams, and ensuring that individuals with ASD receive the necessary treatments within a controlled and supervised environment, thereby contributing to improved outcomes and quality of care.

Region with largest share:

North America holds a significant position and expected to hold a largest share over the forecast period. Due to the advanced healthcare infrastructure, research capabilities, and increasing awareness in the region and the well-established pharmaceutical industry and research institutions drive innovation in ASD interventions. Robust insurance coverage and healthcare accessibility contribute to better treatment access for individuals with ASD. Additionally, North America's collaborative approach among medical professionals, researchers, and advocacy groups supports the development of evidence-based interventions and tailored treatment plans. These factors collectively position North America as a key player in shaping the ASD treatment landscape with a focus on improved outcomes and patient well-being.

Region with highest CAGR:

The Asia Pacific region witnessed highest CAGR in the Autism Spectrum Disorder Treatment market, driven by its large and diverse population, increasing awareness, and growing healthcare infrastructure. The region's rising prevalence of ASD cases has prompted a growing demand for effective interventions, creating opportunities for research, innovation, and investment in treatment approaches. Access to telehealth and digital platforms is expanding, aiding in providing remote support and therapies.

Key players in the market:

Some of the key players in Autism Spectrum Disorder Treatment market include: Curemark, LLC, Eli Lilly and Company, Bristol-Myers Squibb Company, Alembic Pharmaceuticals Limited, Aurobindo Pharma Ltd., Merck & Co., Inc., Axial Therapeutics Inc., Novartis AG., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., PaxMedica, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Pfizer Inc., Q BioMed Inc., Stalicla, Teva Pharmaceutical Industries Ltd., Yamo Pharmaceuticals and Zynerba Pharmaceuticals, Inc.

Key Developments:

  • In December2022, Bened Life released the first gut-brain medical probiotic, Neuralli. Made in the United States and utilizing the patented probiotic strain L. plantarum PS128, Neuralli is designed to promote mental health and support neurological conditions including but not limited to Parkinson's disease (PD) and autism spectrum disorder (ASD).
  • In October2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), reported the highly successful completion of the phase 1b trials for its lead drug candidate STP1.
  • In February 2022,Axial Therapeutics announced that the company has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for their lead candidate AB-2004, a molecular therapeutic targeting the gut is being studied for the treatment of irritability associated with ASD.

Drug Therapies Covered:

  • Antipsychotic Drugs
  • Antidepressants
  • Stimulants
  • Sleep Medications
  • Other Drug Therapies

Diseases Covered:

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Other Diseases

Age Groups Covered:

  • Children
  • Adults

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autism Spectrum Disorder Treatment Market, By Drug Therapy

  • 5.1 Introduction
  • 5.2 Antipsychotic Drugs
  • 5.3 Antidepressants
  • 5.4 Stimulants
  • 5.5 Sleep Medications
  • 5.6 Other Drug Therapies

6 Global Autism Spectrum Disorder Treatment Market, By Disease

  • 6.1 Introduction
  • 6.2 Autistic Disorder
  • 6.3 Asperger Syndrome
  • 6.4 Pervasive Developmental Disorder (PDD)
  • 6.5 Other Diseases

7 Global Autism Spectrum Disorder Treatment Market, By Age Group

  • 7.1 Introduction
  • 7.2 Children
  • 7.3 Adults

8 Global Autism Spectrum Disorder Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Drug Stores & Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Autism Spectrum Disorder Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Curemark, LLC
  • 11.2 Eli Lilly and Company
  • 11.3 Bristol-Myers Squibb Company
  • 11.4 Alembic Pharmaceuticals Limited
  • 11.5 Aurobindo Pharma Ltd.
  • 11.6 Merck & Co., Inc.
  • 11.7 Axial Therapeutics Inc.
  • 11.8 Novartis AG.
  • 11.9 F. Hoffmann-La Roche Ltd
  • 11.10 Otsuka Pharmaceutical Co., Ltd.
  • 11.11 PaxMedica
  • 11.12 Janssen Pharmaceuticals, Inc.
  • 11.13 Johnson & Johnson Services Inc.
  • 11.14 Pfizer Inc.
  • 11.15 Q BioMed Inc.
  • 11.16 Stalicla
  • 11.17 Teva Pharmaceutical Industries Ltd.
  • 11.18 Yamo Pharmaceuticals
  • 11.19 Zynerba Pharmaceuticals, Inc

List of Tables

  • Table 1 Global Autism Spectrum Disorder Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 3 Global Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 4 Global Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 5 Global Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 6 Global Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 7 Global Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 8 Global Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 9 Global Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 10 Global Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 11 Global Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 12 Global Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 13 Global Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 14 Global Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 15 Global Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 16 Global Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 18 Global Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 19 Global Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 20 North America Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 22 North America Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 23 North America Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 24 North America Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 25 North America Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 26 North America Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 27 North America Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 28 North America Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 29 North America Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 30 North America Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 31 North America Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 32 North America Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 33 North America Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 34 North America Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 35 North America Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 North America Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 37 North America Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 38 North America Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 39 Europe Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 41 Europe Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 42 Europe Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 43 Europe Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 44 Europe Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 45 Europe Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 46 Europe Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 47 Europe Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 48 Europe Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 49 Europe Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 50 Europe Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 51 Europe Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 52 Europe Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 53 Europe Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 54 Europe Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 55 Europe Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 56 Europe Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 57 Europe Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 58 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 60 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 61 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 62 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 63 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 64 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 65 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 66 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 67 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 68 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 69 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 70 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 71 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 72 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 73 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 74 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 75 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 76 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 77 South America Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 79 South America Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 80 South America Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 81 South America Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 82 South America Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 83 South America Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 84 South America Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 85 South America Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 86 South America Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 87 South America Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 88 South America Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 89 South America Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 90 South America Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 91 South America Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 92 South America Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 South America Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 94 South America Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 95 South America Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 96 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 98 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 99 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 100 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 101 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 102 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 103 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 104 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 105 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 106 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 107 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 108 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 109 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 110 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 111 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 112 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 113 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)